Cushing's syndrome of nonpituitary causes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 4, 2009, Pages 308-315

  Carroll, Ty B ^a   Findling, James W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adrenocorticotropic hormone independent; Cushing's syndrome; Ectopic adrenocorticotropic hormone syndrome; Exogenous hypercortisolism

Indexed keywords

BUDESONIDE; CHOLESTEROL; CORTICOTROPIN; FLUTICASONE; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; TRIACYLGLYCEROL;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL DISEASE; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALBRIGHT SYNDROME; BREAST CARCINOMA; BRONCHUS CARCINOID; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CUSHING SYNDROME; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; ECTOPIC CORTICOTROPIN PRODUCTION; GASTROINTESTINAL CARCINOMA; GOLD STANDARD; HUMAN; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KIDNEY TUMOR; LEYDIG CELL TUMOR; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MESOTHELIOMA; NEUROBLASTOMA; OVARY CARCINOMA; PANCREAS ISLET CELL TUMOR; PHEOCHROMOCYTOMA; PREVALENCE; PROGNOSIS; PROSTATE CARCINOMA; REVIEW; SALIVARY GLAND TUMOR; STOMACH CARCINOID; THYMOMA; THYROID MEDULLARY CARCINOMA; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

CUSHING SYNDROME; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE;

EID: 67651083828     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32832d8950     Document Type: Review

References (57)

1. Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med 1952; 13:597-614.
2. Swearingen B, Biller BM, Barker FG 2nd, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 1999; 130:821-824.
3. Abraham G. Exogenous Cushing's syndrome induced by surreptitious topical glucocorticosteroid overdose in infants with diaper dermatitis. J Pediatr Endocrinol Metab 2007; 20:1169-1171. (Pubitemid 350285256)
4. Chiang MY, Sarkar M, Koppens JM, et al. Exogenous Cushing's syndrome and topical ocular steroids. Eye 2006; 20:725-727. (Pubitemid 43880593)
5. Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 2005; 34:371-384.
6. Christensson C, Thoren A, Lindberg B. Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects. Drug Saf 2008; 31:965-988. This study highlights that commonly used inhaled glucocorticoids can cause exogenous Cushing's syndrome, despite previously being thought to have little systemic effects.
7. Valin N, De Castro N, Garrait V, et al. Iatrogenic Cushing's Syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature. J Int Assoc Physicians AIDS Care (Chic Ill) 2009; 8:113-121. A comprehensive review of the limited information on the effects of protease inhibitors used in combination with inhaled steroids.
8. Azizi F, Jahed A, Hedayati M, et al. Outbreak of exogenous Cushing's syndrome due to unlicensed medications. Clin Endocrinol (Oxf) 2008; 69:921-925. This case report demonstrates several cases of exogenous Cushing's syndrome caused by drugs of abuse.
9. Razenberg AJ, Elte JW, Rietveld AP, et al. A 'smart' type of Cushing's syndrome. Eur J Endocrinol 2007; 157:779-781.
10. Christy NP. Pituitary-adrenal function during corticosteroid therapy. Learning to live with uncertainty. N Engl J Med 1992; 326:266-267.
11. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647-672. (Pubitemid 28467716)
12. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006; 367:1605-1617.
13. Ambrosi B, Bochicchio D, Ferrario R, et al. Screening tests for Cushing's syndrome. Clin Endocrinol (Oxf) 1990; 33:809-811.
14. Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001; 86:117-123. (Pubitemid 32111743)
15. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40:479-484. (Pubitemid 24194645)
16. Terzolo M, Pia A, Ali A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002; 87:998-1003.
17. Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 2005; 34:423-439. (Pubitemid 40602730)
18. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ('incidentaloma'). Ann Intern Med 2003; 138:424-429. (Pubitemid 36262654)
19. Osella G, Terzolo M, Borretta G, et al. Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J Clin Endocrinol Metab 1994; 79:1532-1539.
20. Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev 1995; 16:460-484.
21. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149:273-285. (Pubitemid 37304697)
22. Caplan RH, Strutt PJ, Wickus GG. Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg 1994; 129:291-296.
23. Terzolo M, Osella G, Ali A, et al. Subclinical Cushing's syndrome in adrenal incidentaloma. Clin Endocrinol (Oxf) 1998; 48:89-97. (Pubitemid 28122438)
24. Minetto M, Reimondo G, Osella G, et al. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int 2004; 15:855-861. (Pubitemid 39506451)
25. Chiodini I, Viti R, Coletti F, et al. Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. Clin Endocrinol (Oxf) 2009; 70:208-213. This recent investigation substantiates prior data that subclinical Cushing's syndrome has deleterious effects on bone density and bone strength and may have clinically important impact on increased fracture risk.
26. Latronico AC, Chrousos GP. Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 1997; 82:1317-1324. (Pubitemid 27200395)
27. Mendonca BB, Lucon AM, Menezes CA, et al. Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood. J Urol 1995; 154:2004-2009.
28. Schorr I, Ney RL. Abnormal hormone responses of an adrenocortical cancer adenyl cyclase. J Clin Invest 1971; 50:1295-1300.
29. Costa MH, Lacroix A. Cushing's syndrome secondary to ACTH-independent macronodular adrenal hyperplasia. Arq Bras Endocrinol Metabol 2007; 51:1226-1237.
30. Beuschlein F, Reincke M, Karl M, et al. Clonal composition of human adrenocortical neoplasms. Cancer Res 1994; 54:4927-4932. (Pubitemid 24289423)
31. Gicquel C, Bertagna X, Le Bouc Y. Recent advances in the pathogenesis of adrenocortical tumours. Eur J Endocrinol 1995; 133:133-144.
32. Malchoff CD, Rosa J, DeBold CR, et al. Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome. J Clin Endocrinol Metab 1989; 68:855-860. (Pubitemid 19089021)
33. Yamada Y, Sakaguchi K, Inoue T, et al. Preclinical Cushing's syndrome due to adrenocorticotropin-independent bilateral adrenocortical macronodular hyperplasia with concurrent excess of gluco- and mineralocorticoids. Intern Med 1997; 36:628-632. (Pubitemid 127513391)
34. Hayashi Y, Takeda Y, Kaneko K, et al. A case of Cushing's syndrome due to ACTH-independent bilateral macronodular hyperplasia associated with excessive secretion of mineralocorticoids. Endocr J 1998; 45:485-491. (Pubitemid 28477659)
35. Goodarzi MO, Dawson DW, Li X, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003; 88:73-77. (Pubitemid 36115145)
36. Kirschner LS, Taymans SE, Stratakis CA. Characterization of the adrenal gland pathology of Carney complex, and molecular genetics of the disease. Endocr Res 1998; 24:863-864.
37. Sarlis NJ, Chrousos GP, Doppman JL, et al. Primary pigmented nodular adrenocortical disease: reevaluation of a patient with Carney complex 27 years after unilateral adrenalectomy. J Clin Endocrinol Metab 1997; 82:1274-1278.
38. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86:4041-4046.
39. Horvath A, Stratakis C. Primary pigmented nodular adrenocortical disease and Cushing's syndrome. Arq Bras Endocrinol Metabol 2007; 51:1238-1244.
40. Fragoso MC, Domenice S, Latronico AC, et al. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 2003; 88:2147-2151. (Pubitemid 36549891)
41. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526-1540. This guideline is a definitive, timely, and evidence-based text on the diagnosis of Cushing's syndrome from all causes.
42. Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008; 93:1553-1562. This extensively researched study is the only meta-analysis that provides information on the diagnostic performance of all the major initial biochemical tests for Cushing's syndrome. (Pubitemid 351656487)
43. Masserini B, Morelli V, Bergamaschi S, et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur J Endocrinol 2009; 160:87-92. This study provides information that suggests that the1mgovernight dexamethasone suppression test is the optimal diagnostic test for subclinical Cushing's syndrome.
44. Nunes ML, Vattaut S, Corcuff JB, et al. Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients. J Clin Endocrinol Metab 2009; 94:456-462. This is the first and only study to directly compare the diagnostic performance of latenight salivary cortisol in hospitalized and ambulatory patients. The data suggest that there is no difference in results from hospitalized and ambulatory patients.
45. Stratakis CA, Sarlis N, Kirschner LS, et al. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Intern Med 1999; 131:585-591. (Pubitemid 29494089)
46. Fagour C, Bardet S, Rohmer V, et al. Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study. Eur J Endocrinol 2009; 160:257-264. This study presents preliminary data on new adrenal scintigraphy. The technique shows promise in differentiating adrenal nodules that currently, or will begin to, autonomously overproduce cortisol from nonfunctioning nodules.
47. Doppman JL, Nieman LK, Travis WD, et al. CT and MR imaging of massive macronodular adrenocortical disease: a rare cause of autonomous primary adrenal hypercortisolism. J Comput Assist Tomogr 1991; 15:773-779.
48. Perrier ND, Kennamer DL, Bao R, et al. Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases. Ann Surg 2008; 248:666-674. This study presents outcomes on a new surgical approach to laparoscopic adrenalectomy. It is an important advance that may improve surgical outcomes and decrease complications.
49. Lamas C, Alfaro JJ, Lucas T, et al. Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia? Longterm follow-up of four cases. Eur J Endocrinol 2002; 146:237-240. (Pubitemid 34162917)
50. Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007; 157:561-569.
51. Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955-4962. (Pubitemid 41159396)
52. Wajchenberg BL, Mendonca BB, Liberman B, et al. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 1994; 15:752-787.
53. Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term followup. J Clin Endocrinol Metab 2006; 91:371-377.
54. Isidori AM, Lenzi A. Ectopic ACTH syndrome. Arq Bras Endocrinol Metabol 2007; 51:1217-1225.
55. Kaltsas GA, Giannulis MG, Newell-Price JD, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84:487-492.
56. Doppman JL, Pass HI, Nieman LK, et al. Detection of ACTH-producing bronchial carcinoid tumors: MR imaging vs CT. AJR Am J Roentgenol 1991; 156:39-43.
57. Pacak K, Ilias I, Chen CC, et al. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D- Phepentetreotide scintigraphy in the localization of ectopic adrenocorticotropinsecreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:2214-2221.